Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Margolin

Showing results (31-40 of 87) with videos related to

Pageof 9
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based ApproachClair J Beard, Shilpa Gupta, Robert J Motzer, et al.
Cancer|May 12, 2006
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignanciesTomasz M Beer, Catherine M Tangen, Craig R Nichols, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II studyBrian I Rini, Susan Halabi, Robert Barrier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Cancer|September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933Sylvia M Lee, James Moon, Bruce G Redman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Pageof 9

Showing results (31-40 of 87) with videos related to

Sort By:
Pageof 9
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based ApproachClair J Beard, Shilpa Gupta, Robert J Motzer, et al.
Cancer|May 12, 2006
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignanciesTomasz M Beer, Catherine M Tangen, Craig R Nichols, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2006
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II studyBrian I Rini, Susan Halabi, Robert Barrier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Cancer|September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933Sylvia M Lee, James Moon, Bruce G Redman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 7, 2012
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeAude G Chapuis, John A Thompson, Kim A Margolin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI studyBrendan D Curti, Jon Richards, John R Hyngstrom, et al.
Pageof 9